Results 281 to 290 of about 62,187 (355)

Bioengineered Bacterial Vesicles and Biomimetic Hybrids Eliminate Biofilms and Balance the Gut Microbiome

open access: yesSmall, EarlyView.
Biomimetic nanocarriers based on liposomes and Myxobacteria outer‐membrane vesicles (OMVs) are effective antibiotic delivery systems. Hybrids have a higher drug loading and can target intracellular pathogens, while OMVs evade immune clearance. Biomimetic nanoantibiotics effectively eliminate the biofilms of Gram‐negative bacteria. Besides, Myxobacteria
Leila Pourtalebi Jahromi   +13 more
wiley   +1 more source

Nanomedicine for Oral Delivery: Strategies to Overcome the Biological Barriers

open access: yesSmall Methods, EarlyView.
Oral delivery is a preferred administration route for many clinical applications, valued for its strong patient compliance. In this review, how nanoparticles are engineered and deployed to overcome the gastrointestinal barriers that impede clinical translation of oral delivery formulations is examined.
Luke J. Kubiatowicz   +5 more
wiley   +1 more source

TNF Inhibitor‐Induced Sarcoidosis‐Like Lesions in Inflammatory Bowel Disease

open access: yesUnited European Gastroenterology Journal, EarlyView.
ABSTRACT Background While tumor necrosis factor (TNF) inhibitors can induce paradoxical reactions, sarcoidosis‐like disease has hardly been reported so far. This study aimed to describe the epidemiological, diagnostic and therapeutic features of TNF inhibitor‐induced sarcoidosis‐like lesions in patients with inflammatory bowel disease.
Zlata Chkolnaia   +12 more
wiley   +1 more source

Filgotinib Is an Effective and Safe Treatment Option for Difficult‐To‐Treat Ulcerative Colitis: Real‐World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry

open access: yesUnited European Gastroenterology Journal, EarlyView.
ABSTRACT Background Filgotinib is a preferential Janus kinase 1 (JAK‐1) inhibitor registered for the treatment of ulcerative colitis (UC). Real‐world effectiveness of filgotinib, especially for difficult‐to‐treat (DTT, failure of ≥ 2 prior advanced therapies) patients, has been scarcely reported.
M. R. Naber   +17 more
wiley   +1 more source

Autologous Adipose Tissue Injection as Treatment for Ileoanal Pouch‐Related Fistulae

open access: yesUnited European Gastroenterology Journal, EarlyView.
ABSTRACT Background Ileal pouch‐anal anastomosis (IPAA) is a standard surgical procedure for ulcerative colitis (UC) and familial adenomatous polyposis. However, pouch‐related fistulae (PRF) are a significant complication. There is no consensus on the optimal treatment for PRF.
Hayder Alqaisi   +3 more
wiley   +1 more source

Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA Registry

open access: yesUnited European Gastroenterology Journal, EarlyView.
ABSTRACT Background Limited data are available on the management and outcomes of postoperative Crohn's disease (CD) in older patients. We aimed to describe the management of CD in the postoperative setting and assess surgical postoperative recurrence (POR) in this population.
Míriam Mañosa   +76 more
wiley   +1 more source

Home - About - Disclaimer - Privacy